Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07113522 · ClinicalTrials.gov registry record · Phase 2

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

A Phase 2 study of Crohn's Disease and Ulcerative Colitis (UC), sponsored by Mirador Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
140
Enrollment target
20
Study locations

NCT07113522 is a Phase 2 study of Crohn's Disease and Ulcerative Colitis (UC) that is actively recruiting participants, run by Mirador Therapeutics. The registered enrollment target is 140 participants, below the 2,413-participant average among 104 other Crohn's Disease trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07113522, a Phase 2 study of Crohn's Disease and Ulcerative Colitis (UC), is actively recruiting participants, sponsored by Mirador Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
140 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.

Conditions Studied

Crohn's Disease Ulcerative Colitis (UC) Inflammatory Bowel Disease (IBD)

Interventions

  • DRUG MT-201
  • DRUG MT-501

Study Locations (20)

Florida

  • Mirador Therapeutics Selected Site - Miami
  • Mirador Therapeutics Selected Site - Miami
  • Mirador Therapeutics Selected Site - Miami
  • Mirador Therapeutics Selected Site - Orlando
  • Mirador Therapeutics Selected Site - Palmetto Bay
  • Mirador Therapeutics Selected Site - Pensacola

Louisiana

  • Mirador Therapeutics Selected Site - Lafayette
  • Mirador Therapeutics Selected Site - Marrero
  • Mirador Therapeutics Selected Site - Shreveport

Arizona

  • Mirador Therapeutics Selected Site - Scottsdale
  • Mirador Therapeutics Selected Site - Sun City

Arkansas

  • Mirador Therapeutics Selected Site - Little Rock
  • Mirador Therapeutics Selected Site - Little Rock

Colorado

  • Mirador Therapeutics Selected Site - Colorado Springs
  • Mirador Therapeutics Selected Site - Littleton

Georgia

  • Mirador Therapeutics Selected Site - Atlanta
  • Mirador Therapeutics Selected Site - Snellville

Illinois

  • Mirador Therapeutics Selected Site - Glenview
  • Mirador Therapeutics Selected Site - Gurnee

Alabama

  • Mirador Therapeutics Selected Site - Birmingham

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2025-06-26
Est. Completion 2028-02-04
Phase Phase 2

Sponsor

Mirador Therapeutics

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07113522

The ClinicalTrials.gov registry entry for NCT07113522 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,413-participant average among 104 other Crohn's Disease trials with a reported enrollment target (94% lower). The listed sponsor is Mirador Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which MT-201 is the first listed.

NCT07113522 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, Louisiana, Arizona.

Frequently Asked Questions

What is clinical trial NCT07113522 about?

NCT07113522 is a clinical study titled "A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease". This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.

What is the current status of trial NCT07113522?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2025-06-26. Estimated completion is 2028-02-04.

What conditions does trial NCT07113522 study?

This clinical trial studies the following conditions: Crohn's Disease, Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD).

What interventions are being tested in trial NCT07113522?

The interventions under investigation include: MT-201 (DRUG), MT-501 (DRUG).

Who is sponsoring clinical trial NCT07113522?

This trial is sponsored by Mirador Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07113522 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Crohn's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Crohn's Disease

All registered trials for this condition

Ulcerative Colitis (UC)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.